Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 10;13:5859. doi: 10.1038/s41467-022-33605-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a Distribution of EGFP expression in the scleral whole-mount 28 days after sub-tenon’s capsule injection of adeno-associated virus serotype DJ (AAV-DJ)-EGFP or AAV-DJ-SaCas9 (as non-fluorescence control); scale bar, 1 mm. b Representative Optical Coherence Tomography images 28 days after of each AAV injection; scale bar, 100 µm. c Expression level of IRE1, PERK, and ATF6 protein 28 days after of AAV-SaCas9 with AAV-gRNA against Eif2ak3 (Gene symbol of PERK, gEig2ak3) and/or Atf6 (gAtf6) injections. d Scleral Eif2ak3 and Atf6 knockdown by AAV-DJ-CRISPR/Cas9 injection into sub-tenon’ capsule. After 28 days injection, gene expression in the sclera determined by qPCR (n = 9, respectively). SaCas9 + gScramble group was assigned a value of 1.0. The p values were determined by one-way ANOVA with Tukey HSD. e Effects of scleral Eif2ak3 and/or Atf6 knockdown on axial elongation (sham: n = 5, gScramble: n = 11, gEif2ak3: n = 9, gAtf6: n = 8, gEif2ak3 + gAtf6: n = 8). The p values were determined by two-tailed Generalized Estimating Equations for five groups comparison (sham vs gScramble vs gEif2ak3 vs gAtf6 vs gEif2ak3 + gAtf6) and Student’s two-tailed t-test for two groups comparison (NL vs −30D). NL: No Lens control, −30D: minus 30 D lens-wearing eye. f Effects of scleral Eif2ak3 and/or Atf6 knockdown on refraction (sham: n = 5, gScramble: n = 9, gEif2ak3: n = 9, gAtf6: n = 8, gEif2ak3 + gAtf6: n = 9). The p values were determined by two-tailed Generalized Estimating Equations for five groups comparison and Student’s two-tailed t-test for two groups comparison. g Effects of scleral Eif2ak3 and/or Atf6 knockdown on VCD + RT (sham: n = 5, gScramble: n = 7, gEif2ak3: n = 7, gAtf6: n = 7, gEif2ak3 + gAtf6: n = 7). The p values were determined by two-tailed Generalized Estimating Equations for five groups comparison and Student’s two-tailed t-test for two groups comparison. Source data are provided as a Source Data file.